Press

Newly issued patent expected to provide protection until at least 2041 and includes composition of matter claims to pharmaceutical compositions within the Company’s proprietary CYB003 deuterated psilocybin analog program – – Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications – – Recently announced positive topline data from Phase 2 study…

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (the “Company” or “FSD“), is pleased to announce that, further to its news release on November 27, 2023, it has closed a non-brokered private placement and issued 24 class A multiple voting shares (“Class A Shares“) of the Company at a price of $1.90 per Class A Share for gross proceeds…

It is that time again when financial reports from the previous quarter start coming out. These documents let us know which companies are moving in a positive direction and which are not. They also show whether the promises made by these companies are being carried out.  Numinus Wellness Inc. is one of the top publicly…

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced achievement of positive results in addiction treatment for its revolutionary treatment targeting cocaine addiction. This groundbreaking development is centered around the company’s innovative psychedelic…